Posted on February 10th, 2021. Posted by Mike Piccinino, CFA
Many public companies withdrew, or never introduced, formal financial guidance in spring 2020 as a result of severe and widespread business disruption and the high level of uncertainty surrounding the COVID-19 pandemic. We are now roughly two weeks into the fourth quarter and fiscal year 2020 earnings reporting season and wanted to share a few notable trends and key considerations that public company management teams should bear in mind as they evaluate whether to give formal financial guidance for 2021.
Continue Reading
Posted on February 9th, 2021. Posted by Michael Robinson
As the Biden Administration begins to implement its agenda, and with the 117th Congress now fully controlled by Democrats, the pace of activity in Washington is poised to accelerate. In this post, we have detailed a cross section of the Biden Administration’s domestic priorities, provided analysis of them, and offered a strategic overview of how companies can position themselves to simultaneously benefit from this activity and, importantly, prepare in the event they become the focus of unwanted scrutiny.
Continue Reading
Posted on January 27th, 2021. Posted by ICR Westwicke
The 2021 Westwicke / ICR Conference went virtual this year — and like many in-person events suddenly turned remote, attendees found new and unexpected opportunities for connecting with each other. Namely, the ability, finally, to be in two meetings at once.
Continue Reading
Posted on January 19th, 2021. Posted by Peter Vozzo
Warren Buffet makes the news each year for his letter to Berkshire Hathaway shareholders. By employing his uniquely wry and contrarian style and covering many topics that have little direct bearing on Berkshire’s results or prospects, Buffet has taken one of the staple obligations of a public company CEO, and turned it into something much larger — a kind of State of the Union from the desk of one of our most important business leaders.
Continue Reading
Posted on December 17th, 2020. Posted by ICR Westwicke
No one could have predicted the events of 2020. However, given the strength and evolution of the healthcare and biotech industry over the past 12 months, the team at Westwicke has some ideas about how the upcoming year may unfold. Below, we provide insight into what the new year may bring.
Continue Reading
Posted on December 10th, 2020. Posted by Chris Brinzey
Every investor’s decision-making process is unique. However, understanding their primary concerns and anticipating common questions can help you better align your message with what the investor needs to hear in order to come to an investment decision.
There are six questions in particular that investors will ask about you and your market opportunity before making an investment decision. Use the checklist below to prepare your answers to these common investor questions prior to your next meeting.
Continue Reading
Posted on November 16th, 2020. Posted by Kate Coyle
After nearly 20 years of working in healthcare communications, the excitement never gets old for me. What’s not to love about an industry that’s critical to life itself, rife with issues and controversy, and delivers a solid dose of the unexpected on a daily basis?
In my mind, a highlight is the problem solving our job requires every day. Whether pursuing an opportunity, managing an issue or leveraging an insight, it’s our responsibility to chart the path forward on behalf of our clients.
Continue Reading
Posted on November 11th, 2020. Posted by Matt Lindberg
After a long period of market uncertainty driven by the COVID-19 pandemic, the second half of 2020 saw market conditions improve for IPOs with a recent flurry of tech companies making their debut. With increased demand to access the public markets, a strong pipeline of companies set to come to market is shaping up quickly for all of 2021.
Continue Reading
Posted on October 30th, 2020. Posted by ICR Westwicke
In the wake of the coronavirus pandemic, the IPO market may never look the same. The swift shift to virtual roadshows, for example, has demonstrated efficiencies that are likely to make digital alternatives stick even after regular business travel resumes. But beyond the operational changes behind preparing a company to go public, the market has seen growing interest in alternatives to the IPO itself.
Continue Reading
Posted on October 21st, 2020. Posted by ICR Westwicke
As life science and medical device companies seek regulatory approval for their products, they will likely encounter difficult disclosure decisions around clinical and regulatory events. Clinical trial data and milestones can present great opportunities as well as significant challenges.
Continue Reading
